Saturday, July 21, 2018
 
 
Company News: Page (1) of 1 - 06/16/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference
- risdiplam (RG7916) is well tolerated at all dose levels with no drug-related safety findings - By PR Newswire This article is no longer available,but here are some related topics.


Page: 1


 





About Video Based Tutorials - Contact Us - Advertise With Us - Privacy Guidelines